A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

Inclusion Criteria:

All of the following conditions must be met for subject enrollment:

* Have fully understood and voluntarily signed the informed consent form ;
* Age ≥ 18 years;
* In phase 1, subjects with histologically confirmed CLL/SLL or B-cell NHL who are relapsed/refractory or intolerable after at least 1 prior line of adequate therapy, and have no better treatment choice as assessed by the investigator;
* In Phase 2, the 6 cohorts had the following specific enrollment criteria and required further treatment:
* Cohort 1: histologically confirmed MCL, failure or intolerance to at least one prior treatment including BTK inhibitor;
* Cohort 2: histologically confirmed MCL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
* Cohort 3: histologically confirmed CLL/SLL, failure or intolerance to at least 1 prior treatment including BTK inhibitor;
* Cohort 4: histologically confirmed CLL/SLL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
* Cohort 5: histologically confirmed other B-NHL, failure or intolerance to at least 1 prior treatment including BTK inhibitor;
* Cohort 6: histologically confirmed other B-NHL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
* In addition to CLL and WM, subjects must have at least one radiographically measurable lesion
* ECOG score 0-2;
* Male or female patients of childbearing potential must agree to use effective methods of contraception

Exclusion Criteria:

* Primary central nervous system lymphoma or lymphoma involving the central nervous system;
* Serological status reflects active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection
* HIV infection;
* Abnormalities in hematology lab results
* Cardiac, hepatic, renal, and coagulation abnormalities
* Concomitant clinically significant systemic active infection uncontrollable after appropriate antibiotics or other treatment;
* Expected survival of no more than 24 weeks as judged by the investigator;
* Major surgery within 4 weeks prior to the first dose of study drug
* Required or received anticoagulant therapy (warfarin, or equivalent vitamin K antagonist, or direct thrombin inhibitor, or factor Xa inhibitor, etc.) within 7 days prior to the first dose of study treatment;
* Had undergone cell transplantation or chimeric antigen receptor T cell (CAR-T) therapy within 60 days prior to enrollment
* Combined with uncontrolled active immune cytopenia
* Previous treatment with non-covalently binding BTK inhibitors (e.g. LOXO-305, MK-1026, etc.);
* Pregnant (positive pregnancy test at screening) or lactating female patients;
* QTcF \> 450 msec in male patients or QTcF \> 470 msec in female patients or other significant ECG abnormalities as judged by the investigator;
* Toxicities due to prior antilymphoma therapy have not stabilized and have not recovered to ≤ Grade 1 (except for clinically insignificant toxicities such as alopecia, etc.);
* History of other malignancies within 5 years prior to enrollment, special cases must be discussed with the medical monitor;
* Prior systemic anti-tumor therapy or investigational therapy received less than 4 weeks or 5 half-lives (whichever is shorter) from the start of the planned study treatment;
* Use of strong CYP3A inhibitors or inducers and proton pump inhibitors within 1 week or 5 half-lives (whichever is shorter) before administration of the first study drug;
* History of acute myocardial infarction, unstable angina, stroke, intracranial hemorrhage or transient ischemic attack within 6 months prior to enrollment; New York Heart Association (NYHA) grade 3 and 4 congestive heart failure;
* Live viral vaccination within 28 days prior to the first dose of study drug;
* Unable to take oral drugs, or have severe gastrointestinal diseases that investigator believes that it may affect the absorption of the study drug;
* Insufficient compliance of patients participating in this clinical study as judged by the investigator;
* Any other disease or condition in the judgment of the investigator that the patient is not suitable for the study drug, or will affect the interpretation of the study results